紅細(xì)胞生成素受體抗體
產(chǎn)品名稱： 紅細(xì)胞生成素受體抗體
英文名稱： EPOR
產(chǎn)品編號(hào)： bs-1424R
產(chǎn)品價(jià)格： null
產(chǎn)品產(chǎn)地： 北京
品牌商標(biāo)： BIOSS
更新時(shí)間： 2025-11-13T16:50:54
使用范圍： WB=1:100-500,ELISA=1:500-1000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,
北京索萊寶科技有限公司
- 聯(lián)系人 : 索萊寶-龔思雨
- 地址 : 北京市北京經(jīng)濟(jì)技術(shù)開發(fā)區(qū)環(huán)科中路16號(hào)26幢3層301
- 郵編 :
- 所在區(qū)域 : 北京
- 電話 : 181****6239 點(diǎn)擊查看
- 傳真 : 點(diǎn)擊查看
- 郵箱 : 3193328036@qq.com
- 二維碼 : 點(diǎn)擊查看
The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. There are several isoforms including: EPOR-F (full length), EPOR-S (soluble form), and EPOR-T (truncated form). Upon erythropoietin (EPO) binding, the EPOR activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to have a role in erythroid cell survival. Defects in the EPOR may produce erythroleukemia and familial erythrocytosis. A functional EPOR is found in the cardiovascular system, including endothelial cells and cardiomyocytes, and data suggest that the EPO/EPO receptor system plays an important role in cardiac function. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis.